A Blueprint for Success: Third Rock Funds $40M Series A
By Catherine Shaffer
Tuesday, April 12, 2011
Third Rock Ventures has funded its largest ever Series A for new start-up Blueprint Medicines, based in Cambridge, Mass. Blueprint was established to develop cancer therapies based on the company's Insights-to-Validation platform and its chemical library. Blueprint's approach is to use cancer genome data to create kinase-targeted cancer therapies using a personalized medicine approach.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.